ARS Pharmaceuticals, Inc. (SPRY) Financials

SPRY Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 287.6 million 226.3 million
Dec. 31, 2025 327.7 million 213.4 million
Sept. 30, 2025 372.8 million 225.1 million
June 30, 2025 313.5 million 121.2 million

SPRY Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -44.9 million 7.4 million
Dec. 31, 2025 -43.5 million 5.7 million
Sept. 30, 2025 -47.2 million 5.7 million
June 30, 2025 -39.6 million 5.4 million

SPRY Net Income

No data available :(

SPRY Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 201.0 million 96.5 million -
Dec. 31, 2025 245.0 million 96.4 million -
Sept. 30, 2025 288.2 million 949000 1.5 million
June 30, 2025 240.1 million - 1.7 million

SPRY Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 99.3 million
Dec. 31, 2025 98.6 million
Sept. 30, 2025 98.8 million
June 30, 2025 98.4 million

SPRY Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 4.3 million 72.2 million -
Dec. 31, 2025 - 3.4 million 60.0 million -
Sept. 30, 2025 197000 2.8 million 74.8 million -
June 30, 2025 51000 4.0 million 54.3 million -

SPRY Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 22.7 million 6.3 million
Dec. 31, 2025 28.1 million 3.2 million
Sept. 30, 2025 32.5 million 8.2 million
June 30, 2025 15.7 million 5.0 million

SPRY Revenue by Segment
Graph available only for paid members. Upgrade to see it.

SPRY

Price: $9.81

52 week price:
6.66
18.90

Earnings Per Share: -2.00 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 850.0 million

Links: